Mesothelioma Peritoneum
7
1
2
2
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
28.6%
2 terminated out of 7 trials
50.0%
-36.6% vs benchmark
0%
0 trials in Phase 3/4
100%
2 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (7)
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma
CAR T Cells in Mesothelin Expressing Cancers
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Thrombin Generation and Platelet Activation in CRS/HIPEC